Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trialMichael Foley, Rasha Al‐Lamee, John R. Davies et al.|The Lancet|2024Cited by 86
Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery DiseaseFlorentina Simader, Amit Kaura, Christopher Rajkumar et al.|Journal of the American College of Cardiology|2024Cited by 36
N-of-1 Trial of Angina Verification Before Percutaneous Coronary InterventionChristopher Rajkumar, Rasha Al‐Lamee, Michael Foley et al.|Journal of the American College of Cardiology|2024Cited by 18
TCT-452 The Role of the Collateral Circulation in Stable Angina: An Invasive Placebo-Controlled Study (ORBITA-STAR)Christopher Rajkumar, Rasha Al‐Lamee, Michael Foley et al.|Journal of the American College of Cardiology|2025Cited by 0
Abstract 4369371: Endocardial to epicardial blood flow ratio predicts the placebo-controlled efficacy of the coronary sinus reducerMichael Foley, Rasha Al‐Lamee, Muhammad Mohsin et al.|Circulation|2025Cited by 0